$XBIO
Xenetic Biosciences, Inc.

2024 Q2 Form 10-Q Financial Statement

#000168316824003172 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $726.4K $510.8K
YoY Change 11.58% -15.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.130M $834.9K
YoY Change 19.46% -9.81%
% of Gross Profit
Research & Development $933.8K $944.3K
YoY Change 3.38% 58.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.064M $1.779M
YoY Change 11.61% 16.98%
Operating Profit -$1.337M -$1.268M
YoY Change 11.62% 38.6%
Interest Expense $63.45K $73.25K
YoY Change -49.68% 35.4%
% of Operating Profit
Other Income/Expense, Net $63.43K $73.30K
YoY Change -56.92% 25.04%
Pretax Income -$1.274M -$1.195M
YoY Change 21.22% 39.53%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.274M -$1.195M
YoY Change 21.22% 39.53%
Net Earnings / Revenue -175.38% -233.96%
Basic Earnings Per Share -$0.83 -$0.78
Diluted Earnings Per Share -$0.83 -$0.78
COMMON SHARES
Basic Shares Outstanding 1.541M shares 1.541M shares
Diluted Shares Outstanding 1.541M shares 1.541M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.299M $7.824M
YoY Change -31.95% -34.77%
Cash & Equivalents $7.299M $7.824M
Short-Term Investments
Other Short-Term Assets $716.4K $552.0K
YoY Change -45.69% -37.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.015M $8.376M
YoY Change -33.46% -34.93%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.018M $1.018M
YoY Change 44.56% 20.6%
Total Long-Term Assets $1.018M $1.018M
YoY Change 44.56% 20.6%
TOTAL ASSETS
Total Short-Term Assets $8.015M $8.376M
Total Long-Term Assets $1.018M $1.018M
Total Assets $9.033M $9.394M
YoY Change -29.15% -31.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $283.6K $210.5K
YoY Change 28.16% -18.79%
Accrued Expenses $1.304M $506.0K
YoY Change 100.61% -15.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.588M $716.5K
YoY Change 82.21% -16.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.588M $716.5K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.588M $716.5K
YoY Change 82.21% -16.33%
SHAREHOLDERS EQUITY
Retained Earnings -$195.7M -$194.4M
YoY Change 2.46% 2.35%
Common Stock $1.544K $1.544K
YoY Change 0.52% -89.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.446M $8.678M
YoY Change
Total Liabilities & Shareholders Equity $9.033M $9.394M
YoY Change -29.15% -31.51%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.274M -$1.195M
YoY Change 21.22% 39.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$525.1K -$1.159M
YoY Change -58.62% 5.16%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -525.1K -$1.159M
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -525.1K -$1.159M
YoY Change -58.62% 5.16%
FREE CASH FLOW
Cash From Operating Activities -$525.1K -$1.159M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1540684 shares
CY2024Q1 us-gaap Cash
Cash
7823701 usd
CY2023Q4 us-gaap Cash
Cash
8983046 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
552043 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
603828 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
8375744 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9586874 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1018352 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1018352 usd
CY2024Q1 us-gaap Assets
Assets
9394096 usd
CY2023Q4 us-gaap Assets
Assets
10605226 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
210483 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
240832 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
506011 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
568753 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
716494 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
809585 usd
CY2024Q1 us-gaap Liabilities
Liabilities
716494 usd
CY2023Q4 us-gaap Liabilities
Liabilities
809585 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1543385 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1543385 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1540684 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1540684 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1544 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1544 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208131009 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208053935 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194429309 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193234196 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
8677602 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9394096 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10605226 usd
CY2024Q1 us-gaap Revenues
Revenues
510817 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
944321 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
595276 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
834910 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
925743 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1779231 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1521019 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1268414 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-915175 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4520 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
73301 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1195113 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-856554 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1540684 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1540684 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1516659 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
77074 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1195113 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
8677602 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68852 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-856554 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12859432 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1195113 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-856554 usd
CY2024Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
77074 usd
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
68852 usd
CY2024Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-51785 usd
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
320445 usd
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-222500 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-93091 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-216791 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1159345 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1102438 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1159345 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1102438 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8983046 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7823701 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11994827 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-07-03
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
77074 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
68852 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40100000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39700000 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001683168-24-003172-index-headers.html Edgar Link pending
0001683168-24-003172-index.html Edgar Link pending
0001683168-24-003172.txt Edgar Link pending
0001683168-24-003172-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20240331.xsd Edgar Link pending
xenetic_10q-3101.htm Edgar Link pending
xenetic_10q-3102.htm Edgar Link pending
xenetic_10q-3201.htm Edgar Link pending
xenetic_i10q-033124.htm Edgar Link pending
xbio-20240331_cal.xml Edgar Link unprocessable
xbio-20240331_def.xml Edgar Link unprocessable
xbio-20240331_lab.xml Edgar Link unprocessable
xbio-20240331_pre.xml Edgar Link unprocessable
xenetic_i10q-033124_htm.xml Edgar Link completed